Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence

[1] Beck A(2013)Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry MAbs. 5 621-623

[2] Reichert JM(2016)A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients Adv Ther. 33 626-642

[3] Chastek B(2016)The changing landscape of biosimilars in rheumatology Ann Rheum Dis. 75 974-982

[4] White J(2015)Health Canada’s perspective on the clinical development of biosimilars and related scientific and regulatory challenges GaBI J. 4 36-41

[5] Van Voorhis D(2015)Monoclonal antibody and fusion protein biosimilars across therapeutic areas: a systematic review of published evidence BioDrugs 45 S1-S10

[6] Tang D(2016)Biosimilars: rationale and current regulatory landscape Semin Arthritis Rheum. 3 36-38

[7] Stolshek BS(2014)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement GaBI Journal. 62 1006-1012

[8] Dörner T(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration J Clin Epidemiol. 62 e1-e34

[9] Strand V(2009)Assessing the quality of reports of randomized clinical trials: is blinding necessary? J Clin Epidemiol. 17 1-12

[10] Cornes P(1996)The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions Control Clin Trials. 52 377-384

[1] Beck A(2013)Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry MAbs. 5 621-623

[2] Reichert JM(2016)A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients Adv Ther. 33 626-642

[3] Chastek B(2016)The changing landscape of biosimilars in rheumatology Ann Rheum Dis. 75 974-982

[4] White J(2015)Health Canada’s perspective on the clinical development of biosimilars and related scientific and regulatory challenges GaBI J. 4 36-41

[5] Van Voorhis D(2015)Monoclonal antibody and fusion protein biosimilars across therapeutic areas: a systematic review of published evidence BioDrugs 45 S1-S10

[6] Tang D(2016)Biosimilars: rationale and current regulatory landscape Semin Arthritis Rheum. 3 36-38

[7] Stolshek BS(2014)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement GaBI Journal. 62 1006-1012

[8] Dörner T(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration J Clin Epidemiol. 62 e1-e34

[9] Strand V(2009)Assessing the quality of reports of randomized clinical trials: is blinding necessary? J Clin Epidemiol. 17 1-12

[10] Cornes P(1996)The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions Control Clin Trials. 52 377-384